BRAF and melanoma: In a recent phase II study in patients with advanced melanoma who harbored an HR mutation, niraparib, a PARPi, demonstrated a disease control rate of 64% and a median PFS of 16 weeks in patients who progressed on PD-1 blockade or BRAF/MEK inhibition.